NU-6027

CAS No. 220036-08-8

NU-6027 ( NU6027;NU 6027 )

Catalog No. M13509 CAS No. 220036-08-8

NU-6027 (NU6027) is an ATP-competitive inhibitor of CDK1 and CDK2 with Ki of 2.5 uM and 1.3 uM respectively.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 34 Get Quote
5MG 55 Get Quote
10MG 91 Get Quote
25MG 186 Get Quote
50MG 295 Get Quote
100MG 441 Get Quote
500MG 981 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    NU-6027
  • Note
    Research use only, not for human use.
  • Brief Description
    NU-6027 (NU6027) is an ATP-competitive inhibitor of CDK1 and CDK2 with Ki of 2.5 uM and 1.3 uM respectively.
  • Description
    NU-6027 (NU6027) is an ATP-competitive inhibitor of CDK1 and CDK2 with Ki of 2.5 uM and 1.3 uM respectively; inhibits human tumor cells with a mean GI50 of 10 ±6 uM; also inhibits cellular ATR (IC50=6.7 uM) and RAD51 focus formation, increases the cytotoxicity of the major classes of DNA-damaging anticancer cytotoxic therapy.
  • Synonyms
    NU6027;NU 6027
  • Pathway
    Angiogenesis
  • Target
    CDK
  • Recptor
    ATR;CDK1;CDK2;DNA-PK
  • Research Area
    Other Indications
  • Indication
    ——

Chemical Information

  • CAS Number
    220036-08-8
  • Formula Weight
    251.30
  • Molecular Formula
    C11H17N5O2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 47 mg/mL (187 mM); Ethanol: 3 mg/mL (11.93 mM); Water: <1 mg/mL ( < 1 mg/ml refers to the product slightly soluble or insoluble )
  • SMILES
    NC1=NC(OCC2CCCCC2)=C(N=O)C(N)=N1
  • Chemical Name
    6-(cyclohexylmethoxy)-5-nitrosopyrimidine-2,4-diamine

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Arris CE, et al. J Med Chem. 2000 Jul 27;43(15):2797-804.
2. Peasland A, et al. Br J Cancer. 2011 Jul 26;105(3):372-81.
3. Boschi D, et al. Eur J Med Chem. 2013 Oct;68:333-8.
molnova catalog
related products
  • Dinaciclib

    A potent and selective CDK inhibitor with IC50 of 1, 1, 3 and 4 nM against CDK2, CDK5, CDK1 and CDK9, respectively.

  • BAY 1251152

    BAY 1251152 is the first potent, selective, orally available PTEFb/CDK9 inhibitor with biochemical IC50 of 9 nM and MOLM13 cell IC50 of 29 nM.

  • CDK4-IN-1

    CDK4 inhibitor is a novel and specific CDK4/Cyclin D1 inhibitor with an IC50 of 10 nM.